OPKO Health, Inc. (NASDAQ:OPK) Receives Average Recommendation of “Hold” from Analysts

OPKO Health, Inc. (NASDAQ:OPK) has received an average recommendation of “Hold” from the five research firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $1.55.

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in shares of OPKO Health during the second quarter worth $55,468,000. AWM Investment Company Inc. acquired a new position in shares of OPKO Health during the second quarter worth about $3,165,000. Bank of New York Mellon Corp purchased a new position in OPKO Health during the second quarter worth about $1,995,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in OPKO Health during the second quarter worth about $618,000. Finally, Legal & General Group Plc acquired a new stake in OPKO Health in the second quarter valued at about $520,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Down 0.6%

OPK opened at $1.56 on Tuesday. The business’s 50-day simple moving average is $1.40 and its 200-day simple moving average is $1.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.93 and a current ratio of 3.35. OPKO Health has a one year low of $0.98 and a one year high of $1.73. The stock has a market capitalization of $1.16 billion, a P/E ratio of -17.33 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last posted its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07. The business had revenue of $163.58 million during the quarter, compared to the consensus estimate of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.19) EPS. Analysts anticipate that OPKO Health will post -0.23 EPS for the current year.

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Its diagnostics business includes BioReference Laboratories, which provides clinical laboratory testing and specialty diagnostic services in the United States, and the 4Kscore test, a blood-based test designed to help assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical activities include products and development programs in areas such as endocrinology, nephrology, and other specialty-care markets.